TRANSCRIPTOME SPECTRA: AGNOSTIC EXPRESSION VARIABLES TO EMPOWER GENOMIC EPIDEMIOLOGY STUDIES

Rosalie G. Waller*, Heidi A. Hanson*, Michael J. Madsen, Brian Avery, Douglas Sborov, Nicola J. Camp

University of Utah

Abstract. Cancers are highly heterogeneous diseases and large molecular datasets are increasingly part of describing an individual's unique experience. Gene expression is particularly attractive because it captures both genetic and environmental consequences. Our new approach, SPECTRA, provides a framework of agnostic multi-gene linear equations to calculate variables tuned to the needs of genomic epidemiology studies. SPECTRA variables are not supervised to an outcome. They are quantitative, linearly uncorrelated variables that retain integrity to the original data and cumulatively explain the majority of the global population variance. Together these variables represent a deep dive into the transcriptome, including both large and small sources of variance. The latter is often over-looked, but holds potential for the identification of smaller groups of individuals with large effects and important for developing precision strategies. Each SPECTRA variable is a quantitative tissue phenotype that can be considered a phenotypic outcome providing new avenues to explore disease risk. Also, as a set of SPECTRA variables, they are ideal for modeling alongside other variables as predictors for any clinical outcome of interest. We demonstrate the flexibility of SPECTRA variables for multiple endpoints using RNA sequencing from 767 myeloma patients in the CoMMpass study. Quantitative transcriptome SPECTRA variables enhance the tools researchers have available for incorporating expression in studies to advance precision screening, prevention, intervention, and survival.

Introduction

Epidemiology is the branch of medicine which deals with the incidence, distribution, and control of disease in the population. To identify risk and prognostic factors and understand cancer phenotypes in the population, numerous data types are collected on study participants. Transcriptomes represent the combined effects of inherited and somatic insults as well as epigenetic factors and thus appeal to researchers interested in both genetic and environmental risk factors. Gene expression studies are gaining momentum in genomic epidemiology studies.[1–13] The need to incorporate transcriptomes in genomic epidemiology brings new demands for techniques designed with this domain in-mind.

Here we develop an approach to determine multi-gene equations and calculate transcriptome variables with desirable attributes for epidemiology studies. Specifically, variables that optimize coverage of the global variance, are quantitative, uncorrelated and that retain integrity to the original data. A ‘variable’, as the term implies, has more power for modeling if it represents variance in the population. Multiple variables may be required for broad coverage (a ‘deep dive’). Knowledge of how much variance transcriptome variables represent is also important to understand limitations of a study. Furthermore, variables that are truly quantitative can achieve greater power than if discretized.[14] Uncorrelated variables provide parsimony in penalized modeling and are often simpler to interpret in multivariable analyses. Finally, integrity of variables to the original data (preservation of differences between samples) is important for interpretation. Our goal for such attributes contrasts with the more common strategy to use transcriptome data to categorize samples/patients, i.e., reducing the transcriptome data to a single variable consisting of mutually exclusive categories, often called ‘subtypes’.

We also focus on agnostic derivation. Current techniques for characterizing transcriptomes largely have a computational biology emphasis, interwoven with and constrained by biological knowledge. While these have had great success advancing our understanding of mechanism and pathway,[15–22] there remains room for complementary approaches. Our agnostic strategy is not due to a disinterest in biological relevance, simply that the sources of

heterogeneity are complex and we require methods that match that complexity. Common diseases, and cancers in particular, are multifactorial, where a wealth of other covariates may be equally important to an endpoint. New approaches that can embrace this complexity will enhance the toolset available for interrogating transcriptomes. Conceptually, the advantage of an agnostic data-driven approach is the liberty to discover signals that may challenge conventional wisdom or defy "known" rules. Understanding mechanism is deferred to later, where specific signals can be explored. Our agnostic approach is complimentary and adds to current approaches for the analysis of tumor etiology, risk, treatment, and mortality.

Finally, our motivation is for universal measures, and hence our approach is unsupervised. SPECTRA produces a framework of multi-gene equations to describe the expression space. Within a dataset, the calculated SPECTRA variables can be used for different outcomes, providing the flexibility to explore the same variables across several different models (e.g. overall survival, progression-free survival and time-to-treatment-failure). This can support interpretation and comparisons, improving the ability to decipher the true nature of associations and explore differences. Furthermore, the same framework of equations can be implemented in external studies.

To satisfy these ideals, the core of our approach utilizes principal components analysis (PCA). PCA is an agnostic and unsupervised procedure that provides an isometry to provide a new set of orthogonal (linearly uncorrelated) variables that optimize representation of the variance. In simple terms, PCA reveals the internal structure of the data in a way that best explains the variance in the data. Paramount in this approach is careful attention to quality control, normalization, and batch correction to ensure the variables capture meaningful variance. The results of the subsequent PCA are: the rotation matrix that describes the multi-gene linear transformations; and the transformed data matrix, the quantitative variables for each individual that we refer to as a *SPECTRA variables,* or simply, *spectra*. Dimension reduction is performed to retain the most important components to a known proportion of variance, i.e. the depth of the dive is measurable. The set of linear equations provides a new reduced-dimension

framework for the expression space. The SPECTRA variables are linearly independent, each providing additional coverage of the variance. We previously used PCA to define a new framework and multi-gene expression variables for the PAM50, a targeted and standardized gene-panel for breast cancer.[1,23] With PCA we reduced the 50 genes to five dimensions using a population cohort of breast tumors. When the framework was implemented in an external dataset of tumors from high-risk breast cancer pedigrees, PCA variables as quantitative phenotypic outcomes proved superior to PAM50 subtypes for gene mapping.[1,24] Implemented in an external clinical trial as predictors, PCA variables for PAM50 were able to predict response to paclitaxel.[23] Here, we extend the approach to the whole transcriptome.

Improved representation of an individual's tissue (normal or malignant) will be vital to improve our ability to identify expression characteristics that are important phenotypic traits (predict disease risk) and/or important expression variables to predict patient outcomes. **Figure 1** uses a color analogy to illustrate the conceptual shift of SPECTRA, contrasting our goal of quantitative variables for direct use in outcome modeling with a more conventional categorization approach using hierarchical clustering. In our approach, the three spectra in Figure 1 (x_R, x_G, x_B) are independent variables that can be directly used to model any outcome (y_i), and other covariates/predictors can also be easily included (Figure 1d). Conversely, unsupervised hierarchical clustering uses the spectra to categorize patients into groups (Figure 1c), flattening the multiple spectra to a single categorical variable and reducing statistical power. For example, in the analogy, x_R cannot be captured by any group ordering and associations for that spectra variable would be lost. An alternate convention, is to supervise clustering to an outcome. But, while supervised clustering can improve power over unsupervised clustering for prediction of a single outcome, it also tethers the groups to the particular trained outcome and doesn't facilitate comparison to other outcomes.

We illustrate SPECTRA using the Multiple Myeloma Research Foundation (MMRF) CoMMpass Study data.[25] We derive the spectra equations (framework) for bulk whole transcriptome RNA sequencing (RNAseq) data from CD138+ myeloma cells. As proof-of-

concept, we utilize the calculated spectra in different regression models to identify associations with several outcomes, including established risk scores, patient characteristics and clinical endpoints.

Results

SPECTRA, a quantitative transcriptome approach

The motivation is the derivation of well-behaved, quantitative variables from RNAseq data to capture transcriptome variation that can be used universally as predictors for any outcome, and as novel phenotypes. The approach requires a dataset to derive the framework of equations for the SPECTRA variables. Then multiple spectra are calculated for each individual in the dataset. An overview of the SPECTRA approach is shown in **Figure 2**. As an agnostic technique, the goal is to retain only those aspects of the RNAseq data that can represent meaningful variance. Accordingly, rigorous quality control (QC), normalization, and batch correction is performed prior to the derivation of the variables. Genes likely to lack precision are removed. Only coding genes with sufficient coverage across the dataset are considered. An internal normalization procedure accounts for feature-length, library size, and RNA composition. This normalization avoids the need for reference samples, real or synthetic, and provides the potential for spectra to be ported to follow-up samples and external datasets. Finally, skew and outliers are dealt with before PCA is performed. Specific details are listed in Methods.

PCA is a well-established, data-driven method that, based on the covariance of a dataset, produces a matrix factorization which is a unique solution of linear transformations (*framework*, rotation matrix) and transformed values (*spectra*, transformed data). The linear transformations preserve the variance in the data, i.e., the transformed values preserve distance between the sample data for individuals. Integrity to the original data provides meaningful comparisons between individuals. The resulting transformed values are quantitative variables that are orthogonal (linearly uncorrelated). For dimension reduction, components are ordered according to the amount of global variance they explain and the first k (S_1, …, S_k) selected, for

which the proportion of total variance explained can be described. This reduces attention from 60,000+ expression features in a transcriptome to a handful of spectra specifically derived to represent independent components of the natural global variation across the dataset studied; precisely the type of variables with power to identify differences and important for prediction. The procedure is unsupervised, describing only intrinsic variance in the data, hence the spectra can be incorporated into modeling any outcome in an unbiased way, and the framework of equations can be implemented in external datasets.

Illustrative case study: CD138+ spectra in multiple myeloma

The ultimate value of SPECTRA will be in the discovery of novel tissue phenotypes and predictors. Here, as proof-of-concept, we present associations between a set of spectra to several well-established outcomes or risk groups across several different model types. These are not presented to suggest spectra could replace current clinical tests, but to illustrate the flexibility of SPECTRA to provide a universal transcriptome framework and set of variables for use in various models with disparate outcomes.

We applied SPECTRA to transcriptome data from the MMRF CoMMpass study.[25] We investigated associations of CD138+ spectra with: 1) existing expression-based risk scores;[26,27] 2) clinically-relevant DNA aberrations; 3) clinical prognostic outcomes; and 4) patient demographic groups with elevated myeloma risk. In addition, we illustrate the potential to track transcriptome changes over time.

The CoMMpass dataset is the most extensive sequencing effort in multiple myeloma patients to date. Multiple myeloma is a malignancy of plasma cells (CD138+ cells). The publicly available transcriptome data (IA14) comprised RNAseq data for 887 CD138+ samples on 794 unique patients. Here, data for 768 patients with treatment naïve samples collected at diagnosis were the focus. We used transcript-based expression estimates from Salmon,[28] generated by the CoMMpass study (https://research.themmrf.org). From the total 54,324 features, 7,436 genes and 767 patients' treatment-naïve CD138+ RNAseq data met quality control. The

transcriptome framework and spectra were derived in quality controlled, normalized and batch corrected data from these treatment naïve samples. The first *k* = 39 spectra (S1—S39) were selected, based on a scree test, which captured $v = 65\%$ of the global variation. No spectra showed association with batch (F-statistic, all $p > 0.8$). The details from each step of the QC process, the equations necessary to calculate the 39 spectra, and the individual-level spectra variables for the patients in the IA14 CoMMpass data are provided in Supplemental Data. In addition, R markdown notebooks containing the code used to generate CD138+ spectra in the IA14 dataset, full model analyses and results are provided in the Supplemental Materials.

As linearly uncorrelated variables, each of the 39 CD138+ spectra captures a different source of variance, and hence any one has the potential to explain patient differences and provide insight. **Figure 3** shows spectra charts for 4 patients, and illustrates that while patients may be similar at a high-level (overall patterning), that individual spectra may not follow that apparent high-level similarity.

In prediction modeling it is perhaps more usually to perform penalized or stepwise techniques to improve fit and parsimony. Here, we forced all 39 spectra into each model for simplicity and to ease comparison across results. Association results for the full 39-spectra models for several different outcomes are described below. Overall model significance and the significance for individual spectra in those models are summarized in **Figure 4**. A regression model produces a predicted value for the outcome. Here we refer to these model-prediction values as poly-spectra liability (**PSL**) scores for an outcome.

CD138+ spectra and established expression-based risk scores. The most widely adopted and first expression risk score in myeloma is the University of Arkansas UAMC 70-gene panel, developed in microarray data, and used to classify patients as low- or high-risk for relapse.[26] Using the established classifier, we calculated each patient's risk UAMC-70 risk score and their risk status (low or high). In a multivariable linear regression with UAMC-70 risk score as a continuous outcome variable, 30 spectra were individually significant (p<0.05, Figure 4) and the

full model predicted the UAMC 70-gene risk score with high accuracy and significance (R^2 = 0.86, $F_{39,727}$ = 118.1, $p < 2.2x10^{-16}$). A more recent risk score is the Shahid Bahonar University of Kerman 17-gene prognostic score (SBUK-17) published in 2020 by Zamani-Ahmadmahmudi et al.[27] We calculated each patient's 17-gene prognostic score. In a linear regression with the 17-gene score as a continuous outcome, 25 spectra were significant (Figure 4) and the full model predicted the 17-gene score with excellent accuracy and extreme significance (R^2 = 0.93, $F_{39,272}$ = 252.9, $p < 2.2x10^{-16}$). **Figure 5** illustrates the high correlation between the model PSL scores and the previously established risk scores showing spectra can recapitulate previously established supervised expression risk scores. These results indicate that the spectra framework captures important prognostic signals.

CD138+ spectra and clinical risk. Large somatic chromosomal DNA aberrations detected by cytogenetics are used clinically to define prognostic risk groups in myeloma.[29] Clinical risk categories defined by mSMART[30] include: high risk (del(17p) and t(14;16)); intermediate risk (amp(1q) and t(4;14)); and standard risk (t(11;14)). Models for each of these five chromosomal aberrations (Figure 4) showed different spectra individually significant, with some spectra unique to only one aberration. Interestingly, while the models for all three translocations and amp(1q) were highly significant (all $p < 2x10^{-10}$), the full 39-spectra model for del(17p) was not. To investigate the possibility that the model was over-parameterized, we repeated the del(17p) analysis using a stepwise procedure. This produced a significant model containing only 3 spectra (p = 0.014, Supplemental material). These results indicate transcriptome spectra capture signal from DNA chromosomal changes in CD138+ cells (**Figure 6a-b**).

The international staging system (**ISS**) for myeloma is also used to classify and stratify patients at diagnosis, based on somatic cytogenetics, levels of beta-2 microglobulin, albumin, and lactate dehydrogenase in the blood.[31] In an ordinal logistic regression with ISS stage at diagnosis as the outcome, 13 spectra were significant, providing a model that significantly

differentiated the three clinical stages (Figure 6c). These results indicate spectra can capture signals for disease stage.

CD138+ spectra and disease course. We used Cox proportional hazards analysis to associate spectra with overall survival (**OS**), and time to first-line treatment failure (**TTF**). Spectra significantly predicted OS (log-rank test, $p = 3.1x10^{-17}$, C-statistic = 0.74), with 12 spectra individually significant. At 1,000 days, the hazards of being in the 10^{th} OS-PSL decile compared with the middle two deciles was 20.5 (8.72-48.17). A Cox proportional hazards model for TTF was also successful (log-rank test, $p = 7.9x10^{-10}$, C-statistic = 0.66), with 7 significant spectra (TTF-PSL at 1,000 days HR = 6.23 (2.29-16.99)). As expected, spectra that were significant in both models had effects in the same direction (Figure 4). Kaplan-Meier curves are shown in **Figure 7**. These results indicate spectra can capture signals for disease course.

CD138+ spectra and demographic risk groups. Myeloma is an adult-onset malignancy, most frequently diagnosed at ages 65-74 years (median 69 years).[32] Incidence is higher in men (8.7 men vs. 5.6 women per 100,000) and patients self-reporting as African American (AA men 16.3, and AA women 11.9 per 100,000). A linear regression with age at diagnosis as a quantitative outcome was significant ($p = 2x10^{-14}$), with 15 individually-significant spectra. Logistic regression models for gender, race (self-reported black or white; other racial categories too small to consider) and Hispanic status were all significant ($p = 4x10^{-9}$, $p = 9x10^{-10}$ and $p = 1x10^{-3}$, respectively) (Figure 4). We note that associations found for demographic risk factors may be complex in nature, as such factors are often social constructs, e.g. race and ethnicity. Transcriptomes are able to harbor the effects of genetic, epigenetic, lifestyle and environmental factors. These results indicate spectra can capture signals originating from demographic risk.

CD138+ spectra for tracking changes over time. The SPECTRA framework provides the equations for the spectra variables such that they can be calculated in follow-up samples to

track changes over time. We illustrate this potential in the eleven MM patients for whom at least three longitudinal CD138+ samples were available in the CoMMpass study. **Figure 8** shows a line graph of the Overall Survival PSL score for these eleven patients over 80 months. In this example, the potential for tracking a patient's increasing hazard as the spectra and PSL score changes over time is illustrated.

Discussion

The promise of personalized prevention, management and treatment is rooted in an ability to describe an individual's unique experience and model important sources of heterogeneity.[33] In many cancers gene expression is an established source of heterogeneity, [34] therefore tools that can take a deeper dive and characterize multiple sources of such heterogeneity will be important to bring this promise to fruition. In particular, for human studies and domains such as epidemiology wishing to model multiple sources of risk in a population, transcriptome variables that can be easily incorporated with other variables are needed. The goal of this study was to provide a technique to derive an agnostic framework of variables for transcriptome data, to empower genomic epidemiology studies. SPECTRA identifies quantitative, orthogonal variables that capture sources of transcriptome variation for use in subsequent modeling. Many applications can benefit from the qualities of spectra variables, and this new framework has the potential to provide utility to numerous study designs and many outcome types, beyond its genomic epidemiology impetus.

Data quality and processing is paramount in the quest to derive informative variables. PCA itself is a simple procedure that provides linear transformations of the data to best represent variance. If the data are rife with batch effects, unstable or non-comparable expression measures, noise will overwhelm authentic variance. Accordingly, our technique intentionally includes strict quality control, zero-handling and normalization procedures, and batch correction (Figure 2). Without these steps, PCA can fail to provide variables with the desired qualities and this may explain why PCA has not been favored in the past. An agnostic

approach permits stringent data culling because the incentive to retain features based on known functional relevance is removed. The impetus is to only retain features which can contribute to meaningful variance and provide informative variables for modeling (quantitative, orthogonal, variance-representing). Of course, the limitation of an agnostic approach is reduced biological interpretation or insight into mechanism of the variables prior to modeling. However, there are already many approaches that take this alternate goal of intermediate interpretation,[17] whose limitations are instead the flexibility of the variables they produce. Hence, SPECTRA offers a new framework for an emerging need in epidemiology, as well as a complementary approach to the current tool set available for all fields.

Beyond the agnosticism taken by our proposed technique, other potential advantages of SPECTRA include its unique solution within a dataset, such that the rank of the dimension reduction can be post-hoc and does not influence the definition of retained dimensions. As a statistically rigorous technique, it also provides a measured dive into the transcriptome. Each dimension (eigenvector $\boldsymbol{q}_s$) iteratively moves quantifiably deeper into the variance of the data (measurable by λ_s). Methods that iteratively find independent components (PCA and independent component analysis) have previously been shown to provide superior coverage of transcriptome data.[22] Retention of components deep in the data, representing small variances (i.e., deep dives) provide potential and power to identify small groups of individuals with large effects in outcome studies. These findings are the 'low hanging fruit' scenarios where precision translation may be more straight-forward. In genetic epidemiology, a rare Mendelian form of a cancer; in a clinical trial, the few patients that respond to a drug. SPECTRA also embraces negative weights. The allowance of negative values in its matrix factorization (**MF**) is often given as a criticism of PCA,[15,35] argued as a conceptual source of its lack of biological interpretability; components may mix biological processes due to a focus on variance. We instead suggest this further opportunity as a complementary tool to existing approaches. Non-negative matrix factorization (**NMF**), arguably the leading approach in the computational biology field, restricts all values in the amplitude (equivalent to $\boldsymbol{Q}^T$ in PCA) and pattern (equivalent to $\boldsymbol{T}^T$ in PCA)

matrices to be non-negative. It is reasoned as a beneficial attribute and natural restriction because expression values themselves cannot be negative. Also, because NMF transformed values represent the proportions of each factor in the original data thus providing a simple interpretation. However, while this is certainly an intuitively simple interpretation, the question may remain as to whether it is an adequate representation when pursuing a biologically-agnostic approach. Furthermore, it is not entirely clear that non-negative values are a natural restriction to *systems of genes*. With its non-negativity restriction, NMF limits itself to identification of groups of over-expressed genes.[15,35] It may not be sufficient to model only neutrality and surplus; deficit may also be key. So, while PCA dimensions may represent mixtures of different biological mechanisms, these may be important combinations. Mixtures of biological processes, including genes acting in opposite directions, may better reflect reality. By embracing negative values, PCA can also capture gene systems in deficit, which may be more difficult to interpret, but may equally be just as important to recognize.

Our myeloma case study illustrated derivation of a transcriptome framework and spectra variables for CD138+ cells, and the application of these in various models (linear, logistic and Cox regression, and ANOVA) with many different outcomes. We showed that the set of 39 agnostic, intrinsic (unsupervised) spectra could significantly capture signals corresponding to published expression-based risk scores from traditional supervised approaches, known clinical DNA-based risk factors, disease stage, disease progression, survival, and demographic risk groups. We also illustrated potential for tracking tissue changes as PSL scores over time. As expected for a framework of agnostically derived variables, not all spectra are relevant to every outcome. Across the 14 models presented, the number of individually significant spectra in a model ranged from 3 to 30, and only one spectra-variable (S30) showed no association with any model. Importantly, these examples show the flexibility of the framework as well as how it can support comparisons across different models and outcomes. For example, our results illustrated how two previously gene-expression prognostic scores could be captured using a single framework and illustrate that they are grossly similar (Figure 4). Hence, the framework has the

potential to provide a bridge to compare various existing categorizations (subtypes) of patients, even when no genes overlap in their signatures, or they predict different outcomes.[36] In this way, spectra provide an alternate to categorical intrinsic subtyping, a well-established practice for many cancers.[37] The ability to predict OS and TTF suggests spectra hold utility in clinical studies predicting disease course. Clinically-relevant stratification may be better represented using thresholds within a transcriptome framework.[23]

The potential for increased power using spectra variables is illustrated by the discovery of novel associations between spectra and patient demographic risk groups with known differences in incidence (age, gender, race). Prior studies, using the UAMC 70-gene panel and a Ki67 proliferation index, were not able to identify gene expression differences in malignant cells from self-reported AA and white patients.[38] We note that the diseases in these demographic groups are not distinct entities; fewer than half the spectra variables differ significantly by these patient demographic groups. However, there are spectra that show differences and these provide new avenues to explore why incidence varies in these groups; key to disease prevention and control. In particular, because transcriptomes capture both the effects of internal (inherited genetics) and external factors (lifestyle, exposures, consequences of access to care), these results can support epidemiology and biosociology investigations into such differences. We provide both the variable framework (equations) and the spectra variables for the CoMMpass patients in Supplementary material to enable further study of spectra in other CoMMpass as well as in additional myeloma samples and cohorts.

There are numerous potential applications beyond those undertaken here that could benefit from a statistically rigorous transcriptome framework of expression variables. As shown previously for the PAM50 panel in breast tumors, differences can be observed between familial and sporadic tissues, suggesting components that are familial,[1] and defining powerful new phenotypes for genetic, exposure, and gene-environment studies. Future avenues for spectra as quantitative phenotypes could include expression-quantitative trait locus analyses, Mendelian

randomization, seeding machine-learning applications,[39] tissue measures for pre-clinical models, and corollary studies in clinical trials.

As for any approach, there are limitations. A key question of one of representation. For epidemiology studies, spectra should ideally be representative of the entire disease population. This requires that the derivation dataset is a random sample from that population, or based on a known selective sampling scheme. While there are many publicly available transcriptome datasets,[40,41] most fall short of this ideal. Thus, spectra variables derived have inherent limitations in representation. An investigator should consider if a derivation dataset is adequate to represent their study goals. We note that the goal of the MMRF CoMMpass study was intentionally designed to represent myeloma patients from diagnosis through treatment, and is the largest existing cohort of treatment-naïve CD138+ transcriptomes, with sampling continuing over time. However, demographic representation of patients was not achieved, and this remains a limitation of that study. Another limitation is that, as a simple variance-based procedure, PCA models all sources of variance in the dataset. If artifacts remain in the data, the resulting spectra will represent these also. To minimize this issue, we employed a strict data quality and batch correction process in our workflow, concentrating only a subset of genes for which PCA is likely to be meaningful: well-mapped, stable, with sufficient depth and with batch correction. We also removed genes known to be unstable across different RNAseq pipelines.[42] A third limitation is the ability to use the framework of spectra in external studies. As a data-driven technique, the complete PCA decomposition is overfit to the derivation dataset. While we focus on the first k spectra (largest k components of variation), selected using a scree test[43] to be those prior to decreasing marginal returns, the stability of spectra across datasets and lack of consistency of transcriptome data across datasets will limit this. Last, SPECTRA is intentionally agnostic, designed for modeling and dimensions are not pre-interpreted for functional relevance. Hence, post-hoc analyses will be required to uncover the mechanism/s that underlie the associations identified.

In conclusion, we present a new technique, SPECTRA, to derive an agnostic transcriptome framework of quantitative, orthogonal variables for a dataset. These multi-gene expression variables are designed specifically to capture transcriptome variation, providing new transcriptome phenotypes and variables for flexible modeling, along with other covariates, to better differentiate individuals for any outcome. Applied to CD138+ transcriptomes for myeloma patients, we defined myeloma spectra and implemented these in many different outcome models. We illustrated an ability to predict prognosis, survival, clinical risk, and provide new insight into potential differences between patients from demographic groups. Fundamentally, the technique shifts from categorization to quantitative measures. SPECTRA variables provide a new paradigm and toolset for exploring transcriptomes that hold promise for new discoveries to advance precision screening, prevention, intervention and survival studies.

Methods

Conceptual construction

Here we establish the matrix factorization (MF) natural for genomic epidemiology. Data matrices, $\boldsymbol{X}$ and $\boldsymbol{T}$, are *oriented with individuals as subjects (n rows) and genes as variables (g columns)*. Given a $n \times g$ design matrix, $\boldsymbol{X}$ (mean-centered expression values for n individuals on g genes), PCA is the MF

$$\boldsymbol{X} = \boldsymbol{T}\boldsymbol{Q}^T \qquad \textit{Equation 1}$$

where $\boldsymbol{T}$ contains the transformed values (the dimension variables), and $\boldsymbol{Q}$ is the PCA 'rotation' matrix. Each row in $\boldsymbol{Q}^T = \left(\boldsymbol{q}_1, \boldsymbol{q}_2, \ldots, \boldsymbol{q}_g\right)^T$ is an orthogonal eigenvector (or component) which holds the coefficients for the linear model to transform the observed gene values into the spectra variables. The set of linear transformations are the transcriptome framework. The rotation matrix can be derived from the eigen decomposition of the covariance matrix, $\boldsymbol{\Sigma}$

$$\boldsymbol{\Sigma} = \boldsymbol{Q}\boldsymbol{\Lambda}\boldsymbol{Q}^T \qquad \textit{Equation 2}$$

where $\boldsymbol{\Sigma}$ is proportional to $\boldsymbol{X}^T\boldsymbol{X}$, and $\boldsymbol{\Lambda}$ is the diagonal matrix of eigenvalues. Each eigenvalue, λ_s, is a scalar indicating the proportion of the global variance represented by the transformed value defined by the s^{th} eigenvector, $\boldsymbol{q}_s$, in $\boldsymbol{Q}$. Eigenvalues are ranked, such that the first PC, defined by $\boldsymbol{q}_1$ captures the most variance, $\boldsymbol{q}_2$ the next highest, and so on. We note that there can only be $\min(n, g)$ non-zero eigenvalues, because by definition, beyond this no variance remains. In most, if not all, existing RNAseq studies, there are more genes than individuals and hence n is the limiting rank.

Dimensionality can be reduced to k dimensions by utilizing $\boldsymbol{Q}_k$; only the first k columns (PCs) of $\boldsymbol{Q}$. After selection of k PCs, transformed values are represented as:

$$\boldsymbol{T}_k = \boldsymbol{X}\boldsymbol{Q}_k \qquad \textit{Equation 3}$$

We note that PCA is deterministic and therefore the selection of k is a post-procedure decision which does not influence the MF. The proportion of variance explained by the retained dimensions ($\sum_{s=1}^{k}\lambda_s/\sum_{\forall s}\lambda_s$) can be used as a measure of coverage.

SPECTRA workflow

Careful attention to quality control, normalization, and batch correction is used to ensure the spectra capture meaningful variation. Gene expression counts from bulk RNAseq are the input data. The four steps in the workflow are: (1) quality control; (2) internal normalization; (3) correction for batch effects; (4) PCA and dimension reduction (Figure 2).

Quality control. QC is essential to ensure the transcriptome dimensions capture meaningful variation across the individuals. Features in the transcriptome likely to be unduly influenced by poor alignment or lacking precision due to sequencing depth were removed as potentials for

introducing spurious and unstable variation. Accordingly, we removed all non-autosomal and non-protein coding genes as well as features with low counts. A feature was considered to have inadequate data for precision if more than 5% of samples had fewer than 100 read counts. After removal of features, individuals were removed from consideration if more than 10% of the remaining features had fewer than 100 read counts.

Normalization. This is required for comparisons across genes and individuals, and includes adjustment for gene length, sequencing depth (library size), and RNA composition. Zero-handling is also necessary to appropriate incorporate counts of zero for a feature or transcript). We chose to use a robust internal (single sample) normalization to obviate the need for a 'reference' sample and to provide the possibility for portability across datasets. While our technique is gene-focused, our processing is designed to handle transcript-based alignment and quantification because these have been suggested to be more accurate.[44] Normalized gene expression estimates, e_g, were calculated according to the following procedure:

$$\mathrm{e}_g = \log_2\left(\frac{\sum_{t=1}^{m}\frac{\mathrm{c}_t+1/m}{\mathrm{l}_t}}{\mathrm{median}\left(\sum_{t=1}^{m}\frac{\mathrm{c}_t+1/m}{\mathrm{l}_t}\right)}\right) \qquad \textbf{\textit{Equation 4}}$$

where c_t is the read count for transcript t, l_t is the transcript length in kilobases (extracted from the GTF used to align and quantify the RNAseq data), and m is the number of transcripts for the gene. Zero-handling is achieved by adding $1/m$ to the transcript counts: $\mathrm{c}_t + 1/m$. Division by l_t corrects for transcript length. Summing the length-corrected transcript counts results in a gene-level count per kilobase (CPK) measure. **Equation 4** may also be used for gene-level read counts (equivalent to m =1). Adjustments for sequencing depth and RNA composition (often referred to as the $size\ factor$) is achieved via division of each gene-based CPK measure by the median of CPK-values for retained features. We note that the more usual upper-quartile adjustment also provides robust internal normalization;[45] however, since our implementation is

post-QC, after numerous features have been removed for low counts, the median is more suitable. Normalized data are log_2 transformed to account for skew. We also truncate outliers beyond the five standard deviation thresholds from the mean of the normalized gene counts to the relevant threshold value.

Batch correction. Sequencing is often generated in batches, and it is necessary to correct for the potential of technical artifacts and any spurious variation introduced. We adjust for sequence batch using ComBat[46] as implemented in the sva R package,[47] with patient characteristics that are unbalanced by batch included as covariates.

PCA. We implement PCA with the covariance matrix. For functions that use singular value decomposition to perform PCA it is necessary to center the expression values first to ensure the MF is performed for the covariance. Expression values (e_g) are centered to the mean across individuals for gene g. These centered data represent the design matrix, $\boldsymbol{X}$ $(n \times g)$ (**Equation 1**) for the PCA. The R core function $prcomp(x = \boldsymbol{X}, center = TRUE, scale = FALSE, retx = TRUE)$ was used to perform PCA. We use a scree test[43] (the inflection point of the rank-ordered plot of λ_s, or elbow method) to select the k spectra to retain. The proportion of variance explained by this k-dimensional space ($\sum_{s=1}^{k} \lambda_s / \sum_{\forall s} \lambda_s$) indicates the depth of the dive in to the transcriptome data.

CD138+ spectra in myeloma

Data were generated as part of the MMRF CoMMpass Study (release IA14)[25] and downloaded from the MMRF web portal (https://research.themmrf.org/). Clinical data and CD138+ RNAseq were available for 781 patients at baseline (newly diagnosed bone marrow samples) and 123 follow-up bone marrow samples. Transcript-based expression estimates processed by Salmon (version 0.7.2) were used. The 768 baseline samples were used in the PCA to derive the CD138+ transcriptome framework and SPECTRA variables. Covariates

included in batch correction were age, gender, overall survival, progression-free survival, and time to first-line treatment failure. The first 39 components were selected based on scree test.[43] All 39 spectra were forced variables in all regression models. To illustrate the flexibility of the transcriptome framework, linear, logistic, and Cox regression were performed for several different clinical outcomes and demographic risk groups. In each analysis, spectra were considered as independent, predictor variables. A likelihood ratio test comparing the fit 39-spectra model to the null model is given for significance of the full model. Individual spectra were considered significant in a model if their coefficients in the model were significantly different from 1.0 ($p<0.05$). For each regression model, the predicted value for the outcome is a linear combination of the spectra. We refer to these as poly-spectra liability (**PSL**) scores for the outcome. To illustrate the potential to track longitudinal changes, spectra and PSL scores were calculated for follow-up longitudinal samples. To enable this, batch corrected gene-level measures for the follow-up samples were centered to the mean of the baseline data ($\bar{\boldsymbol{e}}$), and then multiplied with the rotation matrix ($\boldsymbol{Q}_k$) which holds the linear equations for the spectra framework. All analyses and plotting were carried out using the R statistical programming language.

Data availability. Processed RNAseq data from the CoMMpass Study can be downloaded from https://research.themmrf.org/. Dimension variables for the IA14 CoMMpass data are provided in the Supplement. We also provide the details of the QC process and the transcriptome framework (linear equations) necessary to calculate the 39-spectra variables in other studies in the Supplement.

Code availability. R markdown notebooks used to derive the myeloma transcriptome dimensions and generate the myeloma results are included in the Supplement.

References

1. Madsen, M. J. *et al.* Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at *12q15*. *Cancer Epidemiol Biomarkers Prev* **27**, 644–652 (2018).
2. Sweeney, C. *et al.* Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. *Cancer Epidemiol. Biomarkers Prev.* **23**, 714–724 (2014).
3. Stopsack, K. H. *et al.* Regular aspirin use and gene expression profiles in prostate cancer patients. *Cancer Causes Control* **29**, 775–784 (2018).
4. Wang, S. *et al.* Gene expression in triple-negative breast cancer in relation to survival. *Breast Cancer Res. Treat.* **171**, 199–207 (2018).
5. Bhattacharya, A. *et al.* A framework for transcriptome-wide association studies in breast cancer in diverse study populations. *Genome Biol.* **21**, 42 (2020).
6. Caan, B. J. *et al.* Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. *Cancer Epidemiol. Biomarkers Prev.* **23**, 725–734 (2014).
7. Allott, E. H. *et al.* Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications. *Breast Cancer Res. Treat.* **179**, 185–195 (2020).
8. Troester, M. A. *et al.* Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. *J. Natl. Cancer Inst.* **110**, (2018).
9. Huo, D. *et al.* Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. *JAMA Oncol* **3**, 1654–1662 (2017).

10. Millstein, J. *et al.* Prognostic gene expression signature for high-grade serous ovarian cancer. *Ann. Oncol.* (2020) doi:10.1016/j.annonc.2020.05.019.
11. López, C. *et al.* Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. *Nat Commun* **10**, 1459 (2019).
12. Zhu, B. *et al.* Immune gene expression profiling reveals heterogeneity in luminal breast tumors. *Breast Cancer Res.* **21**, 147 (2019).
13. Zhang, M. *et al.* Characterising cis-regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. *Gut* **67**, 521–533 (2018).
14. Altman, D. G. & Royston, P. The cost of dichotomising continuous variables. *BMJ* **332**, 1080 (2006).
15. Brunet, J.-P., Tamayo, P., Golub, T. R. & Mesirov, J. P. Metagenes and molecular pattern discovery using matrix factorization. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 4164–4169 (2004).
16. Reich, M. *et al.* The GenePattern Notebook Environment. *Cell Syst* **5**, 149-151.e1 (2017).
17. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 15545–15550 (2005).
18. Tamayo, P. *et al.* Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 2907–2912 (1999).
19. Zhang, S., Li, X., Lin, Q., Lin, J. & Wong, K.-C. Uncovering the key dimensions of high-throughput biomolecular data using deep learning. *Nucleic Acids Res.* **48**, e56 (2020).
20. Chen, K. M. *et al.* PathCORE-T: identifying and visualizing globally co-occurring pathways in large transcriptomic compendia. *BioData Min* **11**, 14 (2018).

21. Sompairac, N. *et al.* Independent Component Analysis for Unraveling the Complexity of Cancer Omics Datasets. *Int J Mol Sci* **20**, (2019).

22. Way, G. P., Zietz, M., Rubinetti, V., Himmelstein, D. S. & Greene, C. S. Compressing gene expression data using multiple latent space dimensionalities learns complementary biological representations. *Genome Biol.* **21**, 109 (2020).

23. Camp, N. J. *et al.* Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer. *Breast Cancer Res Treat* **175**, 129–139 (2019).

24. Hanson, H. A. *et al.* Family Study Designs Informed by Tumor Heterogeneity and Multi-Cancer Pleiotropies: The Power of the Utah Population Database. *Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology* **29**, 807–815 (2020).

25. Keats, J. J. *et al.* Interim Analysis Of The Mmrf Commpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles. *Blood* **122**, 532–532 (2013).

26. Shaughnessy, J. D. *et al.* A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. *Blood* **109**, 2276–2284 (2007).

27. Zamani-Ahmadmahmudi, M., Nassiri, S. M. & Soltaninezhad, F. Development of a RNA sequencing-based prognostic gene signature in multiple myeloma. *Br J Haematol* bjh.16744 (2020) doi:10.1111/bjh.16744.

28. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. *Nature Methods* **14**, 417–419 (2017).

29. Paner, A., Patel, P. & Dhakal, B. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. *Blood Rev.* 100643 (2019) doi:10.1016/j.blre.2019.100643.

30. Mikhael, J. R. *et al.* Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. *Mayo Clinic Proceedings* **88**, 360–376 (2013).

31. Palumbo, A. *et al.* Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *JCO* **33**, 2863–2869 (2015).

32. Myeloma - Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/mulmy.html.

33. Ramón y Cajal, S. *et al.* Clinical implications of intratumor heterogeneity: challenges and opportunities. *J Mol Med* **98**, 161–177 (2020).

34. Kwa, M., Makris, A. & Esteva, F. J. Clinical utility of gene-expression signatures in early stage breast cancer. *Nat Rev Clin Oncol* **14**, 595–610 (2017).

35. Stein-O'Brien, G. L. *et al.* Enter the Matrix: Factorization Uncovers Knowledge from Omics. *Trends Genet.* **34**, 790–805 (2018).

36. Szalat, R., Avet-Loiseau, H. & Munshi, N. C. Gene Expression Profiles in Myeloma: Ready for the Real World? *Clin Cancer Res* **22**, 5434–5442 (2016).

37. Dai, X. *et al.* Breast cancer intrinsic subtype classification, clinical use and future trends. *Am J Cancer Res* **5**, 2929–2943 (2015).

38. Manojlovic, Z. *et al.* Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases. *PLoS Genet* **13**, e1007087 (2017).

39. Ma, S. & Dai, Y. Principal component analysis based methods in bioinformatics studies. *Briefings in Bioinformatics* **12**, 714–722 (2011).

40. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–585 (2013).

41. Cancer Genome Atlas Research Network *et al.* The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* **45**, 1113–1120 (2013).

42. Arora, S., Pattwell, S. S., Holland, E. C. & Bolouri, H. Variability in estimated gene expression among commonly used RNA-seq pipelines. *Sci Rep* **10**, 2734 (2020).

43. Cattell, R. B. The Scree Test For The Number Of Factors. *Multivariate Behav Res* **1**, 245–276 (1966).

44. Zhao, S., Xi, L. & Zhang, B. Union Exon Based Approach for RNA-Seq Gene Quantification: To Be or Not to Be? *PLoS ONE* **10**, e0141910 (2015).

45. Shahriyari, L. Effect of normalization methods on the performance of supervised learning algorithms applied to HTSeq-FPKM-UQ data sets: 7SK RNA expression as a predictor of survival in patients with colon adenocarcinoma. *Briefings in Bioinformatics* **20**, 985–994 (2019).

46. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics* **8**, 118–127 (2007).

47. Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* **28**, 882–883 (2012).



Figure 1. **Color analogy to illustrate advantages of spectra variables for modeling**. a) Individual observations of color. b) Dimension Reduction (additive color theory), all colors can be represented using 3 quantitative RGB variables. c) Standard-use, modeling on the 3 RGB variables used to identify structure across samples using hierarchical clustering. This derives groups based on the complete 3-variable RGB profile to derive one polychotomous meta-variable (different groups are non-ordinal levels). d) Genomic epidemiology implementation of spectra variables, multiple separate spectra variables integrated directly into a multi-variable analysis. Each uncorrelated variable to be assessed separately for its predictive value for an outcome. This implementation retains full resolution of the initial data because the variables are quantitative and retain integrity to the initial data. Note, lower resolution versions of x_B and x_G can be achieved using hierarchical groups but the loss of quantification will likely also lose power. x_R cannot be captured by any group ordering and associations for this spectra would be lost using hierarchical groups.



Figure 2. Overview of SPECTRA workflow.



Figure 3. Spectra charts in four patients. For each patient, all 39 spectra are illustrated with the value represented by the bar width and intensity. Color indicates if the patient's spectra value is positive or negative. Each patient has a unique profile across the 39 spectra. At a high-level patients 2497 & 1854 may appear most similar (mostly green) and 2394 & 1392 (mostly blue). However, at a finer resolution, similarities vary. For example, for spectrum S1, 2497 is more similar to 1392, and for spectrum S15, 1854 is more similar to 2394.



Figure 4. Overview of spectra and associations with clinical data. a) Significant associations are shown from regression analyses of the y-axis labels as dependent variables and all 39 spectra included as independent variables. Color represents the direction of the association: blue negative beta, orange positive beta. No dot is shown if the spectra was not significantly associated at $p<0.05$ level. Overall p-value shown at right for each model. b) Percent of the global variance captured by each spectrum. Total variance captured by the 39 spectra shown at right.



Figure 5. Myeloma spectra and established expression scores. Linear regression of the 39 spectra and established gene expression profiles from **a)** University of Alabama School of Medicine 70 gene risk score (UAMS-70) and **b)** Shahid Bahonar University of Kerman 17-gene prognostic score (SBUK-17). **c)** Waterfall plot of all patients UAMS-70 score predicted by linear regression of the 39 spectra classified by UAMS-70 high or low risk. Inflection point at UAMS-70 high risk cutoff determined by clustering.



Figure 6. Myeloma spectra and clinical or demographic risk. a) Poly-spectra liability (PSL) scores of logistic regression of **a)** tumor amplification chr1q, **b)** tumor translocation chr11;16, **c)** international tumor stage at diagnosis, **d)** gender, and e) self-reported black or white race.

a) Overall survival, 179 events, C = 0.74, p = 3.1×10^{-17}



b) Time to first line treatment failure, 369 events, C = 0.66, p = 7.9×10^{-10}



Figure 7. Myeloma spectra and disease course. Kaplan-Myer curves for **a)** overall survival and **b)** time to first line treatment failure. Cox proportional hazards analysis were conducted including all 39 spectra. Poly-spectra liability scores split into tertiles are displayed by time in days.



Figure 8. Myeloma spectra and tumor changes over time. Overall survival poly-spectra liability (PSL) score shown for eleven patients with RNAseq at multiple timepoints. Dot indicates sequencing and shows the overall survival PSL score at that timepoint. Final narrow rectangle shows the month after diagnosis the patient died (filled) or was last known alive (open).